Advances in Phenotypic Drug Discovery

The next Meetup of our drug development series will host Alastair King, PhD, and focus on drug discovery trends & new insights from phenotypic approaches.

Dr. King will provide updates on drug discovery trends, including techniques and considerations for phenotypic drug discovery approaches. Attention will be given to fibrosis as an exemplar case study, in the context of novel discovery as well as repurposing strategies.

Alastair has over 20 years of scientific research experience, with a specific focus on drug discovery in the oncology and inflammation therapeutic areas and use of cellular assays to profile and advance drug leads. He has held previous roles at Indiana University, SmithKline Beecham, GlaxoSmithKline, and Johnson & Johnson, and is currently the Scientific Director for the OncoPanel and Biomarker Services cellular phenotypic platforms at Eurofins Discovery. Alastair has deep experience with all stages of drug discovery from target validation and prioritization, through supporting high-throughput screening campaigns, hit-to-lead chemistry, and lead optimization, to the generation of IND packages for clinical entry. He has provided leadership for international strategic initiatives and drug discovery teams, including that which discovered dabrafenib (Tafinlar®), and has coordinated due diligence studies on external assets for in-licensing and subsequent clinical development (e.g. trametinib/Mekinist®). Alastair received his Ph.D. in biochemistry from the University of Southampton, is an AACR member, and has received numerous awards in recognition of his work.

Please RSVP to receive a link to the on-line event.
For any questions please contact us: [rea@YDL-ventures.com](http://mailto:rea@ydl-ventures.com/)